Trinity Biotech
TRIB
79 hedge funds and large institutions have $203M invested in Trinity Biotech in 2016 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 36 increasing their positions, 22 reducing their positions, and 11 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1% less capital invested
Capital invested by funds: $205M → $203M (-$2.18M)
4% less funds holding
Funds holding: 82 → 79 (-3)
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
99% less call options, than puts
Call options by funds: $1K | Put options by funds: $117K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$3.7M |
| 2 |
PCA
Prospect Capital Advisors
Sausalito,
California
|
+$3.57M |
| 3 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$2.54M |
| 4 |
LAM
Lapides Asset Management
Greenwich,
Connecticut
|
+$1.6M |
| 5 |
RA
Royce & Associates
New York
|
+$1.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair Investment Management
Chicago,
Illinois
|
-$8.86M |
| 2 |
Millennium Management
New York
|
-$3.67M |
| 3 |
DM
Deerfield Management
New York
|
-$2.89M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$1.1M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1M |
TRIB Hedge Fund Activity: Q1 2016 in Review
79 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q1 2016, worth a combined $203M — down 1.1% from $205M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TRIB and 8 opened new positions — a net loss of 3 holders — while 22 trimmed existing stakes and 36 added.
The largest buyer was Park West Asset Management, adding an estimated $3.7M. The largest seller was William Blair Investment Management, exiting entirely with an estimated $8.86M sold.
- 79 institutional investors held Trinity Biotech (TRIB) as of Q1 2016, down from 82 in Q4 2015.
- Funds reported $203M of Trinity Biotech stock for Q1 2016, down 1.1% quarter-over-quarter.
- 8 funds opened new Trinity Biotech positions in Q1 2016 and 11 closed out, a net change of -3 holders.
- The largest Trinity Biotech buyer in Q1 2016 was Park West Asset Management, an estimated $3.7M added.
- The largest Trinity Biotech seller in Q1 2016 was William Blair Investment Management, an estimated $8.86M sold.
Based on aggregated 13F filings for Q1 2016.